Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8874014 | 0.76 | EGFR (0.58) | EGFRPIK3CDPIK3CACSNK1DCSNK1E | |
| SCHEMBL30466554 | 0.76 | EGFR (0.48) | EGFRPIK3CDPIK3CAFGFR4 | |
| SCHEMBL7222157 | 0.76 | EGFR (0.59) | EGFRPIK3CDPIK3CACSNK1DCSNK1E | |
| SCHEMBL6765023 | 0.76 | EGFR (0.48) | EGFRPIK3CDPIK3CAFGFR4 | |
| SCHEMBL7920056 | 0.74 | EGFR (0.47) | EGFRPIK3CDPIK3CAFGFR4 | |
| SCHEMBL27918893 | 0.74 | EGFR (0.52) | EGFRPIK3CDPIK3CACSNK1DCSNK1E | |
| SCHEMBL921632 | 0.72 | EGFR (1.00) | EGFRPIK3CDPIK3CAFGFR4HSP90AA1 | |
| SCHEMBL29504195 | 0.72 | EGFR (1.00) | EGFRPIK3CDPIK3CAFGFR4HSP90AA1 | |
| SCHEMBL29925974 | 0.71 | LCK (0.45) | EGFRPIK3CDPIK3CA | |
| SCHEMBL31352848 | 0.70 | EGFR (0.52) | EGFRPIK3CDPIK3CANOS2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | EGFR 4865/4885PDPK1 1157/4885PIK3CD 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.